Denali Therapeutics (DNLI) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Denali Therapeutics (DNLI) is Neutral.

The composite score behind that read is -0.13, weighing +0.20 of bullish evidence against -0.36 bearish.

Denali Therapeutics last closed at $19.45, +4.18% on the session.

Against the IVW growth benchmark the position is +3.38% over the forecast window.

The read is built from 15 underlying insights — 2 bullish and 13 bearish.

Agreement across those insights is 87%.

20 graded predictions for DNLI so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Denali Therapeutics in the 17th percentile on return on equity, where 100 is best.

Denali Therapeutics is classified under Health Care / Biotechnology, with a market capitalisation of $2.98B.

StockMap tracks Denali Therapeutics as the 71st largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite Denali Therapeutics ranks 248th of 381 in the group, against a group median of -0.08.